Tuberculosis Drug Discovery: Challenges and New Horizons

Autor(es)

Fernandes, Guilherme F. S. ; Thompson, Andrew M. ; Castagnolo, Daniele ; Denny, William A. ; Dos Santos, Jean L.

• Tipo de documento: Artigo Científico
• Fonte: Journal of Medicinal Chemistry; v. 65, n. 11, p. 43-pg., 2022-06-09.

Resumo

Over the past 2000 years, tuberculosis (TB) has claimed more lives than any other infectious disease. In 2020 alone, TB was responsible for 1.5 million deaths worldwide, comparable to the 1.8 million deaths caused by COVID-19. The World Health Organization has stated that new TB drugs must be developed to end this pandemic. After decades of neglect in this field, a renaissance era of TB drug discovery has arrived, in which many novel candidates have entered clinical trials. However, while hundreds of molecules are reported annually as promising anti-TB agents, very few successfully progress to clinical development. In this Perspective, we critically review those anti-TB compounds published in the last 6 years that demonstrate good in vivo efficacy against Mycobacterium tuberculosis. Additionally, we highlight the main challenges and strategies for developing new TB drugs and the current global pipeline of drug candidates in clinical studies to foment fresh research perspectives. (AU)

• Processo FAPESP: 18/11079-0 - Síntese e atividade antituberculose de novos derivados N-óxidos planejados para o tratamento da tuberculose multirresistente
• Beneficiário: Jean Leandro dos Santos
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 16/09502-7 - Planejamento, síntese e atividade antituberculose de novas oxazolidinonas úteis ao tratamento da tuberculose multirresistente
• Beneficiário: Guilherme Felipe dos Santos Fernandes
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 18/17739-2 - Síntese de Novos Derivados de Nitroimidazooxazina Planejados como Agentes Antituberculose
• Beneficiário: Guilherme Felipe dos Santos Fernandes
• Modalidade de apoio: Bolsas no Exterior - Estágio de Pesquisa - Doutorado
• Processo FAPESP: 20/13279-7 - Síntese e avaliação anti-Mycobacterium tuberculosis de novos derivados nitroimidazooxazina úteis para o tratamento da tuberculose multirresistente
• Beneficiário: Jean Leandro dos Santos
• Modalidade de apoio: Auxílio à Pesquisa - Regular